2024 Europe Automated Microbiology Market: Supplier Shares and Segment Forecasts for 100 Tests - France, Germany, Italy, Spain, UK - Molecular Diagnostics, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, Immunodiagnost

2024 Europe Automated Microbiology Market: Supplier Shares and Segment Forecasts for 100 Tests - France, Germany, Italy, Spain, UK - Molecular Diagnostics, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, Immunodiagnostics

LeadingMarketResearch.com's new report is a five-country strategic analysis of major business opportunities emerging in the automated microbiology market during the next five years. The report examines key trends in the major European countries (France, Germany, Italy, Spain, UK); reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for molecular diagnostic, microbial identification, antibiotic susceptibility, blood culture, urine screening and immunodiagnostic procedures, as well as over 100 infectious disease tests by assay, application, market segment, and country; profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers.

Rationale

The level of automation in the microbiology laboratory has been lagging behind that of other major clinical laboratory segments, such as chemistry and hematology. The slow acceptance of the technology is in part due to the complexity of developing automation suitable for microbiology tests.

The introduction of automated microbiology instrumentation has been delayed by a number of intrinsic and technical problems. The diffusion of automated microbiology systems, once the technology was developed, has not matched that of other automated laboratory technologies. The acquisition of automation in microbiology has been slowed by forces less easily identifiable than the effects of various reimbursement plans. Some laboratorians still believe that current instrumentation is not the ultimate technology and expect better automation on the horizon.

The driving force behind the need for rapid reporting of microbiological test results is the clinical relevance in a time of financial austerity, a time when cost and health care effectiveness to the patient and diagnostician looms ever larger, and where after-the-fact results at high expense are coming under severe scrutiny worldwide.

This comprehensive five-country report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding European microbiology market, in evaluating emerging opportunities and developing effective business strategies.

Geographic Coverage

France, Germany, Italy, Spain, UK

Market Segmentation Analysis

Sales and market shares for major suppliers by individual test and country.
Volume and sales forecasts for over 100 infectious disease assays by individual test and country:
Test volume estimates by method (molecular, serology/immunodiagnostics, culture/microscopy).
Review of the market dynamics, trends, structure, size, growth and major suppliers by country.

Specimen Types

Urine
Sterile Fluids: Blood, Serum, CSF
Throat Swabs, Respiratory Secretions
Genital Secretions
Stool
Abscess/Wound
Sputum
Saliva

Applications

Microbial Identification
Antibiotic Susceptibility
Urine Screening
Blood Culture

Review of Major Automated Systems

Review of major automated molecular diagnostic, multipurpose, specialized, microbial identification, antibiotic susceptibility, blood culture, urine screening, and immunodiagnostic analyzers.

The report profiles analyzers manufactured by Abbott, Affymetrix, Beckman Coulter/Cepheid/Danaher, Becton Dickinson, bioMerieux, Bio-Rad, Diamedix, DiaSorin, Eiken Chemical, Elitech Group, Enzo Biochem, Fujifilm Wako, Fujirebio, Grifols, GSK Biologicals, Hologic, Labcorp, Leica Biosystems, Lonza, PerkinElmer, Qiagen, QuidelOrtho, Roche, Scienion, SeraCare, Siemens Healthineers, Takara Bio, Thermo Fisher.

Infectious Diseases Analyzed in the Report

AIDS/HIV, Adenovirus, Aeromonads, Bartonella, Blastocystis Hominis, Campylobacter, Candida, Carbapenemase, Chancroid, Chlamydia, Clostridium, Coronavirus, Coxsackievirus, Cryptosporidium, Cyclospora, CMV, E. Coli, Echovirus, Encephalitis, Enterovirus, EBV, Giardia, Gonorrhea, Granuloma Inguinale, Hantavirus, H. Pylori, Hepatitis, Herpes, Influenza, Legionella, Lyme Disease, Lymphogranuloma, Malaria, Measles, Meningitis, Microsporidium, Mononucleosis, Mumps, Mycoplasma, Norovirus, HPV, Parvovirus, Pneumonia, Polyomaviruses, Pseudomonas, Rabies, RSV, Rhinovirus, Rotavirus, Rubella, Salmonella, Septicemia, Shigella, Staphylococci, Streptococci, Syphilis, Toxoplasmosis, Trichomonas, TB, Vibrio, West Nile, Yersinia.

Technology Review

Assessment of molecular diagnostic, monoclonal antibody, immunoassay, and other technologies and their potential applications for the microbiology market.

Global listings of companies developing or marketing microbiology products by individual test.

Competitive Assessments

Strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new products in R&D.

The companies analyzed in the report include Abbott, Affymetrix, Beckman Coulter/Danaher, Becton Dickinson, bioMerieux, Bio-Rad, Cepheid, Diamedix, DiaSorin, Eiken Chemical, Elitech Group, Enzo Biochem, Fujirebio, Grifols, GSK Biologicals, Hologic, Leica Biosystems, Lonza, Ortho-Clinical Diagnostics, PerkinElmer, Qiagen, Roche, Scienion, Sequenom, SeraCare, Siemens Healthineers, Takara Bio, Thermo Fisher, Wako.

Opportunities and Strategic Recommendations

Emerging opportunities for new analyzers, reagents kits, IT and other products with significant market appeal during the next five years.

Design criteria for decentralized testing products.

Alternative market penetration strategies.

Potential market entry barriers and risks.

Please note: The delivery time for the electronic version of this report is between 1-3 business days to allow the preparation of an updated version prior to dispatch.